Cytokinetics (CYTK) vs Protagonist Therapeutics (PTGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Protagonist Therapeutics (PTGX) has outperformed Cytokinetics (CYTK) over the past year, gaining 115.2% versus a gain of 1.6%. Over five years, PTGX leads with a +355.0% price change compared with +65.7% for CYTK. Protagonist Therapeutics is the larger company by market cap ($9.12 billion vs $8.65 billion), about 1.1 times the size, while Cytokinetics is growing revenue faster (+376.6% vs -89.4%).
Protagonist Therapeutics converts more of its revenue into profit, with a net margin of -282.8% versus -891.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CYTK | PTGX |
|---|---|---|
| Share price | $62.23 | $140.92 |
| Market cap | $8.65B | $9.12B |
| 1-day change | +1.81% | 0.00% |
| YTD return | -3.81% | +61.35% |
| 1-year return | +1.58% | +115.24% |
| 5-year return | +65.68% | +355.02% |
| P/E ratio (TTM) | — | 136.82 |
| EPS (TTM) | $-7.22 | $1.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $88.04M | $46.02M |
| Revenue growth (YoY) | +376.56% | -89.41% |
| Net income (latest FY) | $-784.96M | $-130.15M |
| Operating margin | -695.44% | -343.63% |
| Net margin | -891.60% | -282.83% |
| 52-week high | $88.31 | $160.81 |
| 52-week low | $54.30 | $65.56 |
| Distance from 52-week high | -29.54% | -12.37% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +76.62% | +23.96% |
| Average volume | 1.96M | 632.64K |
| Shares outstanding | 139.02M | 64.71M |
| Employees | 673 | 141 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PTGX has outperformed CYTK by 113.7 percentage points over the past year.
- Protagonist Therapeutics is more profitable, keeping -282.8 cents of every revenue dollar as net income versus -891.6 cents for Cytokinetics.
- Cytokinetics grew revenue faster in its latest fiscal year (+376.56% vs -89.41%).
About Cytokinetics
CYTK stock →Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM.
Health Care · Biotechnology: Pharmaceutical Preparations · 673 employees
About Protagonist Therapeutics
PTGX stock →Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 141 employees
CYTK vs PTGX FAQ
Which is bigger, Cytokinetics or Protagonist Therapeutics?
Protagonist Therapeutics (PTGX) is larger, with a market capitalization of $9.12B compared with $8.65B for Cytokinetics (CYTK).
Which stock has performed better over the past year, CYTK or PTGX?
PTGX returned +115.24% over the past 12 months, compared with +1.58% for CYTK (price return, excluding dividends). Past performance does not predict future results.
Are Cytokinetics and Protagonist Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.